ibuprofen has been researched along with Apoplexy in 20 studies
Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine
Excerpt | Relevance | Reference |
---|---|---|
" In a previous randomized trial we observed that treatment with high-dose acetaminophen (paracetamol) led to a reduction of body temperature in patients with acute ischemic stroke, even when they had no fever." | 9.10 | Effect of paracetamol (acetaminophen) and ibuprofen on body temperature in acute ischemic stroke PISA, a phase II double-blind, randomized, placebo-controlled trial [ISRCTN98608690]. ( Dippel, DW; Kappelle, LJ; Koudstaal, PJ; Meijer, RJ; van Breda, EJ; van der Worp, HB; van Gemert, HM, 2003) |
"The aim was to assess whether using LSPS matching would enable the evaluation of paracetamol, compared to ibuprofen, and increased risk of myocardial infarction, stroke, gastrointestinal (GI) bleeding, or acute renal failure." | 7.96 | Channeling Bias in the Analysis of Risk of Myocardial Infarction, Stroke, Gastrointestinal Bleeding, and Acute Renal Failure with the Use of Paracetamol Compared with Ibuprofen. ( Berlin, JA; Fife, D; Ryan, PB; Schuemie, MJ; Swerdel, J; Weinstein, RB, 2020) |
" We determined whether paracetamol or ibuprofen use is associated with major cardiovascular events (MACE) or major bleeding in 19 120 patients with recent ischemic stroke or transient ischemic attack of mainly atherothrombotic origin included in the Prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) trial." | 7.83 | Paracetamol, Ibuprofen, and Recurrent Major Cardiovascular and Major Bleeding Events in 19 120 Patients With Recent Ischemic Stroke. ( Amarenco, P; Bousser, MG; Chamorro, A; Fisher, M; Ford, I; Fox, KM; Gonzalez-Valcarcel, J; Hennerici, MG; Labreuche, J; Mattle, HP; Rothwell, PM; Sissani, L; Steg, PG; Vicaut, E, 2016) |
"Seventy-five (3 x 25) patients with acute ischaemic stroke confined to the anterior circulation will be randomised to treatment with either: 400 mg ibuprofen, 1000 mg acetaminophen, or with placebo 6 times daily during 5 days." | 7.71 | PISA. The effect of paracetamol (acetaminophen) and ibuprofen on body temperature in acute stroke: protocol for a phase II double-blind randomised placebo-controlled trial [ISRCTN98608690]. ( Dippel, DW; Kappelle, J; Koudstaal, PJ; Meijer, R; van Breda, EJ; van der Worp, B; van Gemert, M, 2002) |
" Ten normal volunteer subjects underwent 3 randomized treatment sessions: aspirin 325 mg alone, ibuprofen 400 mg alone, and ibuprofen 400 mg, followed by dosing with aspirin 325 mg 2 hours thereafter." | 6.73 | Effects of ibuprofen on the magnitude and duration of aspirin's inhibition of platelet aggregation: clinical consequences in stroke prophylaxis. ( Bates, V; Gengo, FM; Gengo, MF; Mager, DE; Rainka, M; Robson, M; Rubin, L, 2008) |
" In a previous randomized trial we observed that treatment with high-dose acetaminophen (paracetamol) led to a reduction of body temperature in patients with acute ischemic stroke, even when they had no fever." | 5.10 | Effect of paracetamol (acetaminophen) and ibuprofen on body temperature in acute ischemic stroke PISA, a phase II double-blind, randomized, placebo-controlled trial [ISRCTN98608690]. ( Dippel, DW; Kappelle, LJ; Koudstaal, PJ; Meijer, RJ; van Breda, EJ; van der Worp, HB; van Gemert, HM, 2003) |
"Overall, the use of NSAIDs is not associated with an increased risk of hemorrhagic stroke, although this risk was modestly significantly elevated in diclofenac and meloxicam users." | 4.93 | Nonaspirin Nonsteroidal Anti-Inflammatory Drugs and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Observational Studies. ( Matteson, EL; Thongprayoon, C; Ungprasert, P, 2016) |
"The aim was to assess whether using LSPS matching would enable the evaluation of paracetamol, compared to ibuprofen, and increased risk of myocardial infarction, stroke, gastrointestinal (GI) bleeding, or acute renal failure." | 3.96 | Channeling Bias in the Analysis of Risk of Myocardial Infarction, Stroke, Gastrointestinal Bleeding, and Acute Renal Failure with the Use of Paracetamol Compared with Ibuprofen. ( Berlin, JA; Fife, D; Ryan, PB; Schuemie, MJ; Swerdel, J; Weinstein, RB, 2020) |
" We determined whether paracetamol or ibuprofen use is associated with major cardiovascular events (MACE) or major bleeding in 19 120 patients with recent ischemic stroke or transient ischemic attack of mainly atherothrombotic origin included in the Prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) trial." | 3.83 | Paracetamol, Ibuprofen, and Recurrent Major Cardiovascular and Major Bleeding Events in 19 120 Patients With Recent Ischemic Stroke. ( Amarenco, P; Bousser, MG; Chamorro, A; Fisher, M; Ford, I; Fox, KM; Gonzalez-Valcarcel, J; Hennerici, MG; Labreuche, J; Mattle, HP; Rothwell, PM; Sissani, L; Steg, PG; Vicaut, E, 2016) |
" High-dose ibuprofen and diclofenac were associated with increased risk of ischemic stroke [hazard ratio 2·15 (95% confidence interval 1·66-2·79) and 2·37 (confidence interval 1·99-2·81), respectively]." | 3.80 | Use of nonsteroidal anti-inflammatory drugs among healthy people and specific cerebrovascular safety. ( Andersson, C; Fosbøl, EL; Gislason, GH; Kober, L; Olesen, JB; Olsen, AM; Torp-Pedersen, C, 2014) |
"This was a post hoc analysis from the INternational VErapamil Trandolapril STudy (INVEST), which enrolled patients with hypertension and coronary artery disease." | 3.77 | Harmful effects of NSAIDs among patients with hypertension and coronary artery disease. ( Bavry, AA; Cooper-Dehoff, RM; Gong, Y; Handberg, EM; Khaliq, A; Pepine, CJ, 2011) |
" Naproxen users had the lowest adjusted rates of serious coronary heart disease (myocardial infarction, coronary heart disease death) and serious cardiovascular disease (myocardial infarction, stroke)/death from any cause, with respective incidence rate ratios (relative to NSAID nonusers) of 0." | 3.75 | Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. ( Arbogast, PG; Castellsague, J; Chung, CP; Daugherty, JR; García-Rodríguez, LA; Murray, KT; Ray, WA; Stein, CM; Varas-Lorenzo, C, 2009) |
"To estimate the net cardiovascular (CV) (coronary heart disease, stroke, congestive heart failure), and gastrointestinal (GI) (peptic ulcer complications) risk-benefit public health impact of the use of celecoxib compared to non-selective NSAIDs in the arthritis population." | 3.74 | Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level. ( Castellsague, J; Maguire, A; Perez-Gutthann, S; Varas-Lorenzo, C, 2007) |
"Seventy-five (3 x 25) patients with acute ischaemic stroke confined to the anterior circulation will be randomised to treatment with either: 400 mg ibuprofen, 1000 mg acetaminophen, or with placebo 6 times daily during 5 days." | 3.71 | PISA. The effect of paracetamol (acetaminophen) and ibuprofen on body temperature in acute stroke: protocol for a phase II double-blind randomised placebo-controlled trial [ISRCTN98608690]. ( Dippel, DW; Kappelle, J; Koudstaal, PJ; Meijer, R; van Breda, EJ; van der Worp, B; van Gemert, M, 2002) |
" Ten normal volunteer subjects underwent 3 randomized treatment sessions: aspirin 325 mg alone, ibuprofen 400 mg alone, and ibuprofen 400 mg, followed by dosing with aspirin 325 mg 2 hours thereafter." | 2.73 | Effects of ibuprofen on the magnitude and duration of aspirin's inhibition of platelet aggregation: clinical consequences in stroke prophylaxis. ( Bates, V; Gengo, FM; Gengo, MF; Mager, DE; Rainka, M; Robson, M; Rubin, L, 2008) |
"Fever in acute stroke is associated with poor prognosis, but evidence-based recommendations on antipyretic therapy are lacking." | 1.36 | [Antipyretic strategies for acute stroke: a nationwide survey among German stroke units]. ( Beck, A; Kallmünzer, B; Kollmar, R; Schwab, S, 2010) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 8 (40.00) | 29.6817 |
2010's | 11 (55.00) | 24.3611 |
2020's | 1 (5.00) | 2.80 |
Authors | Studies |
---|---|
Weinstein, RB | 1 |
Ryan, PB | 1 |
Berlin, JA | 1 |
Schuemie, MJ | 1 |
Swerdel, J | 1 |
Fife, D | 1 |
Chen, YR | 1 |
Hsieh, FI | 1 |
Chang, CC | 1 |
Chi, NF | 1 |
Wu, HC | 1 |
Chiou, HY | 1 |
Bhala, N | 1 |
Emberson, J | 1 |
Merhi, A | 1 |
Abramson, S | 1 |
Arber, N | 1 |
Baron, JA | 1 |
Bombardier, C | 1 |
Cannon, C | 1 |
Farkouh, ME | 1 |
FitzGerald, GA | 1 |
Goss, P | 1 |
Halls, H | 1 |
Hawk, E | 1 |
Hawkey, C | 1 |
Hennekens, C | 1 |
Hochberg, M | 1 |
Holland, LE | 1 |
Kearney, PM | 1 |
Laine, L | 1 |
Lanas, A | 1 |
Lance, P | 1 |
Laupacis, A | 1 |
Oates, J | 1 |
Patrono, C | 1 |
Schnitzer, TJ | 1 |
Solomon, S | 1 |
Tugwell, P | 1 |
Wilson, K | 1 |
Wittes, J | 1 |
Baigent, C | 1 |
Greifzu, F | 2 |
Pielecka-Fortuna, J | 1 |
Kalogeraki, E | 1 |
Krempler, K | 1 |
Favaro, PD | 1 |
Schlüter, OM | 1 |
Löwel, S | 2 |
Ungprasert, P | 1 |
Matteson, EL | 1 |
Thongprayoon, C | 1 |
Gonzalez-Valcarcel, J | 1 |
Sissani, L | 1 |
Labreuche, J | 1 |
Bousser, MG | 1 |
Chamorro, A | 1 |
Fisher, M | 1 |
Ford, I | 1 |
Fox, KM | 1 |
Hennerici, MG | 1 |
Mattle, HP | 1 |
Rothwell, PM | 1 |
Steg, PG | 1 |
Vicaut, E | 1 |
Amarenco, P | 1 |
Iannuccelli, C | 1 |
Di Franco, M | 1 |
Pulcinelli, FM | 1 |
Den Hertog, HM | 1 |
van der Worp, HB | 2 |
Tseng, MC | 1 |
Dippel, DW | 3 |
Ray, WA | 1 |
Varas-Lorenzo, C | 2 |
Chung, CP | 1 |
Castellsague, J | 2 |
Murray, KT | 1 |
Stein, CM | 1 |
Daugherty, JR | 1 |
Arbogast, PG | 1 |
García-Rodríguez, LA | 1 |
Kallmünzer, B | 1 |
Beck, A | 1 |
Schwab, S | 1 |
Kollmar, R | 1 |
Bavry, AA | 1 |
Khaliq, A | 1 |
Gong, Y | 1 |
Handberg, EM | 1 |
Cooper-Dehoff, RM | 1 |
Pepine, CJ | 1 |
Schmidt, S | 1 |
Schmidt, KF | 1 |
Kreikemeier, K | 1 |
Witte, OW | 2 |
Jablonka, JA | 1 |
Kossut, M | 1 |
Liguz-Lecznar, M | 1 |
Fosbøl, EL | 1 |
Olsen, AM | 1 |
Olesen, JB | 1 |
Andersson, C | 1 |
Kober, L | 1 |
Torp-Pedersen, C | 1 |
Gislason, GH | 1 |
van Breda, EJ | 2 |
van Gemert, HM | 1 |
Meijer, RJ | 1 |
Kappelle, LJ | 1 |
Koudstaal, PJ | 2 |
Maguire, A | 1 |
Perez-Gutthann, S | 1 |
Gengo, FM | 1 |
Rubin, L | 1 |
Robson, M | 1 |
Rainka, M | 1 |
Gengo, MF | 1 |
Mager, DE | 1 |
Bates, V | 1 |
Schafer, A | 1 |
van der Worp, B | 1 |
van Gemert, M | 1 |
Meijer, R | 1 |
Kappelle, J | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)[NCT02741817] | Phase 4 | 20 participants (Actual) | Interventional | 2016-06-26 | Completed | ||
Astaxanthin Effects on Osteoarthritis Associated Pain and Inflammatory Indicators[NCT03664466] | 0 participants (Actual) | Interventional | 2021-04-29 | Withdrawn (stopped due to Inadequate funding) | |||
Analgesic Efficacy of Preoperative Oral Administration of Dexketoprofen Trometamol in Third Molar Surgery, Compared to Postoperative Administration[NCT02380001] | Phase 4 | 60 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
Treatment Efficacy of 'Shinbaro Capsule' in the Treatment of Hand Osteoarthritis: Randomized, Double-blinded, Placebo-controlled, Multicenter Investigator Initiated Trial.[NCT01910116] | Phase 2/Phase 3 | 220 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
Effects on Omission of NSAIDs on the Consumption of Opioids in the Standard Analgesic Regimen After Elective Laparoscopic Colorectal Cancer Resection in an ERAS Setting. A Retrospective Single-center Cohort Study.[NCT04448652] | 502 participants (Actual) | Observational [Patient Registry] | 2015-01-01 | Completed | |||
A Phase IIa Randomized, Active-controlled, Double-blind, Dose-escalation Study in Patients With Vulvovaginal Candidiasis to Evaluate Dose Response Relationship of Clinical Efficacy, Safety and Tolerability of Topically Administered ProF-001[NCT03115073] | Phase 2/Phase 3 | 84 participants (Actual) | Interventional | 2017-04-04 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"Change in AUSCAN function score at 12 weeks from baseline = Function score at 12 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 12 weeks
Intervention | units on a scale (Median) |
---|---|
Shinbaro | -11 |
Placebo | -2.9 |
"Change in AUSCAN function score at 16 weeks from baseline = Function score at 16 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
Intervention | units on a scale (Median) |
---|---|
Shinbaro | -9.9 |
Placebo | -4.8 |
"Change in AUSCAN function score at 4 weeks from baseline = Function score at 4 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Basline and 4 weeks
Intervention | units on a scale (Median) |
---|---|
Shinbaro | -6.8 |
Placebo | -3.7 |
"Change in AUSCAN function score at 8 weeks from baseline = Function score at 8 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 8 weeks
Intervention | units on a scale (Median) |
---|---|
Shinbaro | -9.7 |
Placebo | -4.8 |
"Change in AUSCAN pain score at 4 weeks from baseline = Pain at 4 weeks (0-100) - Pain at baseline (0-100).~AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 4 weeks
Intervention | units on a scale (Median) |
---|---|
Shinbaro | -9.0 |
Placebo | -2.2 |
"Change in AUSCAN pain score at 12 weeks from baseline = Pain at 12 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline, 12 weeks
Intervention | units on a scale (Median) |
---|---|
Shinbaro | -14.6 |
Placebo | -8.0 |
"Change in AUSCAN pain score at 16 weeks from baseline = Pain at 16 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
Intervention | units on a scale (Median) |
---|---|
Shinbaro | -15.6 |
Placebo | -4.4 |
"Change in AUSCAN pain score at 8 weeks from baseline = Pain at 8 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline, 8 weeks
Intervention | units on a scale (Median) |
---|---|
Shinbaro | -13.4 |
Placebo | -2.2 |
"Change in AUSCAN stiffness score at 12 weeks from baseline = Stiffness at 12 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Basline and 12 weeks
Intervention | units on a scale (Median) |
---|---|
Shinbaro | -14.0 |
Placebo | -11.0 |
"Change in AUSCAN stiffness score at 16 weeks from baseline = Stiffness at 16 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline, 16 weeks
Intervention | units on a scale (Median) |
---|---|
Shinbaro | -10.0 |
Placebo | -8.0 |
"Change in AUSCAN stiffness score at 4 weeks from baseline = Stiffness at 4 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 4 weeks
Intervention | units on a scale (Median) |
---|---|
Shinbaro | -9.0 |
Placebo | -6.0 |
"Change in AUSCAN stiffness score at 8 weeks from baseline = Stiffness at 8 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: baseline and 8 weeks
Intervention | units on a scale (Median) |
---|---|
Shinbaro | -12.0 |
Placebo | -6 |
Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment (NCT01910116)
Timeframe: Baselie and 16 weeks
Intervention | participants (Number) |
---|---|
Shinbaro | 55 |
Placebo | 40 |
"Change in Patient global assessment (PGA) at 12 weeks from baseline = PGA at 12 weeks (0-100)- PGA score at baseline (0-100). GPA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 12 weeks
Intervention | units on a scale (Median) |
---|---|
Shinbaro | -11.0 |
Placebo | -6.0 |
"Change in Patient global assessment (PGA) at 16 weeks from baseline = PGA at 16 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
Intervention | units on a scale (Median) |
---|---|
Shinbaro | -10.0 |
Placebo | -8.5 |
"Change in Patient global assessment (PGA) at 4 weeks from baseline = PGA at 4 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 4 weeks
Intervention | units on a scale (Median) |
---|---|
Shinbaro | -9.0 |
Placebo | -3.0 |
"Change in Patient global assessment (PGA) at 8 weeks from baseline = PGA at 8 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 8 weeks
Intervention | units on a scale (Median) |
---|---|
Shinbaro | -10.0 |
Placebo | -6.0 |
"Change in Physician global assessment (PhGA) at 12 weeks from baseline = PhGA at 12 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 12 weeks
Intervention | units on a scale (Median) |
---|---|
Shinbaro | -19.0 |
Placebo | -13 |
"Change in Physician global assessment (PhGA) at 16 weeks from baseline = PhGA at 16 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
Intervention | units on a scale (Median) |
---|---|
Shinbaro | -12 |
Placebo | -6.5 |
"Change in Physician global assessment (PhGA) at 4 weeks from baseline = PhGA at 4 weeks (0-100)- PhGA score at baseline (0-100). GPA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: baseline and 4 weeks
Intervention | units on a scale (Median) |
---|---|
Shinbaro | -12 |
Placebo | -7.0 |
"Change in Physician global assessment (PhGA) at 8 weeks from baseline = PhGA at 8 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 8 weeks
Intervention | units on a scale (Median) |
---|---|
Shinbaro | -16.0 |
Placebo | -11.5 |
"Change in Swollen joint count (SJC) at 12 weeks from baseline = SJC at 12 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 12 weeks
Intervention | Joints (Median) |
---|---|
Shinbaro | 0 |
Placebo | 0 |
"Change in Swollen joint count (SJC) at 16 weeks from baseline = SJC at 16 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
Intervention | Joints (Median) |
---|---|
Shinbaro | 0 |
Placebo | 0 |
"Change in Swollen joint count (SJC) at 4 weeks from baseline = SJC at 4 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 4 weeks
Intervention | Joints (Median) |
---|---|
Shinbaro | 0 |
Placebo | 0 |
"Change in Swollen joint count (SJC) at 8 weeks from baseline = SJC at 8 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 8 weeks
Intervention | Joints (Median) |
---|---|
Shinbaro | 0 |
Placebo | 0 |
"Change in Tender joint count (TJC) at 12 weeks from baseline = TJC at 12 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 12 weeks
Intervention | joints (Median) |
---|---|
Shinbaro | -2.0 |
Placebo | -1.0 |
"Change in Tender joint count (TJC) at 16 weeks from baseline = TJC at 16 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
Intervention | joints (Median) |
---|---|
Shinbaro | -2.0 |
Placebo | -1.0 |
"Change in Tender joint count (TJC) at 4 weeks from baseline = TJC at 4 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 4 weeks
Intervention | joints (Median) |
---|---|
Shinbaro | -1 |
Placebo | 0 |
"Change in Tender joint count (TJC) at 8 weeks from baseline = TJC at 8 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 8 weeks
Intervention | Joints (Median) |
---|---|
Shinbaro | -1.0 |
Placebo | -1.0 |
yes = AAP rescue use, no = no AAP rescue use (NCT01910116)
Timeframe: 12 weeks and 16 weeks
Intervention | participants (Number) | |
---|---|---|
yes | no | |
Placebo | 2 | 104 |
Shinbaro | 4 | 105 |
yes = AAP rescue use, no = no AAP rescue use (NCT01910116)
Timeframe: 4 weeks and 8 weeks
Intervention | participants (Number) | |
---|---|---|
yes | no | |
Placebo | 7 | 99 |
Shinbaro | 10 | 99 |
yes = AAP rescue use, no = no AAP rescue use (NCT01910116)
Timeframe: 8 weeks and 12 weeks
Intervention | participants (Number) | |
---|---|---|
yes | no | |
Placebo | 4 | 102 |
Shinbaro | 4 | 105 |
yes = AAP rescue use, no = no AAP rescue use (NCT01910116)
Timeframe: Baseline 4 weeks
Intervention | participants (Number) | |
---|---|---|
yes | no | |
Placebo | 4 | 102 |
Shinbaro | 7 | 102 |
Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment (NCT01910116)
Timeframe: Baseline and 12 weeks
Intervention | participants (Number) | |
---|---|---|
responder | nonresponder | |
Placebo | 43 | 63 |
Shinbaro | 62 | 47 |
Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment (NCT01910116)
Timeframe: Baseline and 8 weeks
Intervention | participants (Number) | |
---|---|---|
responder | nonresponder | |
Placebo | 38 | 68 |
Shinbaro | 56 | 53 |
Outcome Measures in Rheumatology-Osteoarthritis Research Society International (OMERACT-OARSI) Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment (NCT01910116)
Timeframe: Baseline and 4 weeks
Intervention | participants (Number) | |
---|---|---|
Responder | Nonresponder | |
Placebo | 32 | 74 |
Shinbaro | 48 | 61 |
3 reviews available for ibuprofen and Apoplexy
Article | Year |
---|---|
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Nonaspirin Nonsteroidal Anti-Inflammatory Drugs and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Observational Studies.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cerebral Hemorrhage; Diclofenac; Humans; Ibuprof | 2016 |
Cooling therapy for acute stroke.
Topics: Acetaminophen; Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Dipyrone; Humans; Hypothermia | 2009 |
2 trials available for ibuprofen and Apoplexy
Article | Year |
---|---|
Effect of paracetamol (acetaminophen) and ibuprofen on body temperature in acute ischemic stroke PISA, a phase II double-blind, randomized, placebo-controlled trial [ISRCTN98608690].
Topics: Acetaminophen; Acute Disease; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroida | 2003 |
Effects of ibuprofen on the magnitude and duration of aspirin's inhibition of platelet aggregation: clinical consequences in stroke prophylaxis.
Topics: Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Cross-Over S | 2008 |
15 other studies available for ibuprofen and Apoplexy
Article | Year |
---|---|
Channeling Bias in the Analysis of Risk of Myocardial Infarction, Stroke, Gastrointestinal Bleeding, and Acute Renal Failure with the Use of Paracetamol Compared with Ibuprofen.
Topics: Acetaminophen; Acute Kidney Injury; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Ag | 2020 |
Effect on Risk of Stroke and Acute Myocardial Infarction of Nonselective Nonsteroidal Anti-Inflammatory Drugs in Patients With Rheumatoid Arthritis.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; | 2018 |
Environmental enrichment extends ocular dominance plasticity into adulthood and protects from stroke-induced impairments of plasticity.
Topics: Animals; Diazepam; Dominance, Ocular; Environment; Female; GABA Modulators; Ibuprofen; Interneurons; | 2014 |
Paracetamol, Ibuprofen, and Recurrent Major Cardiovascular and Major Bleeding Events in 19 120 Patients With Recent Ischemic Stroke.
Topics: Acetaminophen; Aged; Analgesics, Non-Narcotic; Brain Ischemia; Cardiovascular Diseases; Female; Hemo | 2016 |
Letter by Iannuccelli et al Regarding Article, "Paracetamol, Ibuprofen, and Recurrent Major Cardiovascular and Major Bleeding Events in 19 120 Patients With Recent Ischemic Stroke".
Topics: Acetaminophen; Brain Ischemia; Hemorrhage; Humans; Ibuprofen; Stroke | 2016 |
Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Studies; C | 2009 |
[Antipyretic strategies for acute stroke: a nationwide survey among German stroke units].
Topics: Acetaminophen; Analgesics, Non-Narcotic; Cryotherapy; Data Collection; Dipyrone; Germany; Hospitals, | 2010 |
Harmful effects of NSAIDs among patients with hypertension and coronary artery disease.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Celec | 2011 |
Global impairment and therapeutic restoration of visual plasticity mechanisms after a localized cortical stroke.
Topics: Animals; Cerebrum; Dominance, Ocular; Ibuprofen; Male; Mice; Mice, Inbred C57BL; Neuronal Plasticity | 2011 |
Experience-dependent brain plasticity after stroke: effect of ibuprofen and poststroke delay.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cerebral Cortex; Cyclooxygenase 2; Ibuprofen; Male | 2012 |
Use of nonsteroidal anti-inflammatory drugs among healthy people and specific cerebrovascular safety.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Brain Ischemia; Cohort Studies; Denmark; Diclofenac; | 2014 |
Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular D | 2007 |
Take aspirin before ibuprofen, not after.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Administration Schedule; Drug Interactions; H | 2006 |
My doctor recently recommended that I take low-dose aspirin to minimize the risk of a heart attack or stroke. I routinely take ibuprofen for arthritis pain. Do I need both, and is it safe to combine the two?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Interactions; Humans; Ibuprofen; Myocardial I | 2000 |
PISA. The effect of paracetamol (acetaminophen) and ibuprofen on body temperature in acute stroke: protocol for a phase II double-blind randomised placebo-controlled trial [ISRCTN98608690].
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Body Temperature; Clinical Trials, Phase II | 2002 |